Literature DB >> 11313367

Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.

J L Pooley1, W R Heath, K Shortman.   

Abstract

Mouse spleen contains three distinct mature dendritic cell (DC) populations (CD4(+)8(-), CD4(-)8(-), and CD4(-)8(+)) which retain a capacity to take up particulate and soluble AGS: Although the three splenic DC subtypes showed similar uptake of injected soluble OVA, they differed markedly in their capacity to present this Ag and activate proliferation in OVA-specific CD4 or CD8 T cells. For class II MHC-restricted presentation to CD4 T cells, the CD8(-) DC subtypes were more efficient, but for class I MHC-restricted presentation to CD8 T cells, the CD8(+) DC subtype was far more effective. This differential persisted when the DC were activated with LPS. The CD8(+) DC are therefore specialized for in vivo cross-presentation of exogenous soluble Ags into the class I MHC presentation pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313367     DOI: 10.4049/jimmunol.166.9.5327

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  177 in total

1.  Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery.

Authors:  W Asavaroengchai; Y Kotera; J J Mulé
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

2.  Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells.

Authors:  Oliver Schulz; Caetano Reis e Sousa
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

3.  A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes.

Authors:  Stephen T Ferris; Javier A Carrero; James F Mohan; Boris Calderon; Kenneth M Murphy; Emil R Unanue
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

4.  Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance.

Authors:  Yeonseok Chung; Dong-Hyeon Kim; Seung-Ho Lee; Chang-Yuil Kang
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

Review 5.  Cross-presentation: dendritic cells and macrophages bite off more than they can chew!

Authors:  Sven Brode; Paul A Macary
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

Review 6.  Transcriptional programming of the dendritic cell network.

Authors:  Gabrielle T Belz; Stephen L Nutt
Journal:  Nat Rev Immunol       Date:  2012-01-25       Impact factor: 53.106

7.  C1q protein binds to the apoptotic nucleolus and causes C1 protease degradation of nucleolar proteins.

Authors:  Yitian Cai; Boon Heng Dennis Teo; Joo Guan Yeo; Jinhua Lu
Journal:  J Biol Chem       Date:  2015-07-31       Impact factor: 5.157

8.  The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.

Authors:  Irina Caminschi; Anna I Proietto; Fatma Ahmet; Susie Kitsoulis; Joo Shin Teh; Jennifer C Y Lo; Alexandra Rizzitelli; Li Wu; David Vremec; Serani L H van Dommelen; Ian K Campbell; Eugene Maraskovsky; Hal Braley; Gayle M Davey; Patricia Mottram; Nicholas van de Velde; Kent Jensen; Andrew M Lew; Mark D Wright; William R Heath; Ken Shortman; Mireille H Lahoud
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

9.  Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.

Authors:  Michael Y Gerner; Kerry A Casey; Matthew F Mescher
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Stress-induced glucocorticoids at the earliest stages of herpes simplex virus-1 infection suppress subsequent antiviral immunity, implicating impaired dendritic cell function.

Authors:  Michael D Elftman; John T Hunzeker; Jennifer C Mellinger; Robert H Bonneau; Christopher C Norbury; Mary E Truckenmiller
Journal:  J Immunol       Date:  2010-01-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.